Health utilities using the EQ-5D in studies of cancer

PharmacoEconomics

Volumn 25, Issue 5, 2007, Pages 365-384

  Pickard, A Simon ^a,b   Wilke, Caitlyn T ^a   Lin, Hsiang Wen ^a   Lloyd, Andrew ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER; DATA BASE; DIGESTIVE SYSTEM CANCER; EMBASE; HODGKIN DISEASE; HUMAN; MEDLINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REVIEW; SCORING SYSTEM; VALIDITY; VISUAL ANALOG SCALE;

HUMANS; NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE;

EID: 34248326442     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725050-00002     Document Type: Review

References (54)

1. World Cancer Report. Lyon: IARC Press, 2003
2. Jemal A, Murphy T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30
3. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365-76
4. de Haes J, Curran D, Young T, et al. Quality of life evaluation in oncological clinical trials: the EORTC model. The EORTC Quality of Life Study Group. Eur J Cancer 2000; 36 (7): 821-5
5. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1 (1): 79 [online]. Available from URL: http://www.hqlo.com/content/1/1/79 [Accessed 2007 Apr 19]
6. Feeny D, Furlong W, Boyle M, et al. Multiattribute health-status classification systems: health utilities index. Pharmacoeconomics 1995; 7 (6): 490-502
7. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33 (5): 337-43
8. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35 (11): 1095-108
9. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002; 11 (4): 341-53
10. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005; 43 (7): 736-49
11. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18 (18): 3302-17
12. National Institute for Clinical Excellence (UK). Guide to the methods of technology appraisal. London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/page.aspx?o=201973 [Accessed 2007 Apr 17]
13. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine: Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276 (14): 1172-7
14. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354 (9193): 1896-900
15. Lee SH, Kim DJ, Oh JH, et al. Validation of a functional evaluation system in patients with musculoskeletal tumors. Clin Orthop Relat Res 2003; 411: 217-26
16. van Roijen L, Nijs HG, Avezaat CJ, et al. Costs and effects of microsurgery versus radiosurgery in treating acoustic neuroma. Acta Neurochir (Wien) 1997; 139 (10): 942-8
17. Conner-Spady BL, Cumming C, Nabholtz JM, et al. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 2005; 36 (3): 251-9
18. Jansen SJ, Otten W, van de Velde CJ, et al. The impact of the perception of treatment choice on satisfaction with treatment, experienced chemotherapy burden and current quality of life. Br J Cancer 2004; 91 (1): 56-61
19. Polsky D, Keating NL, Weeks JC, et al. Patient choice of breast cancer treatment: impact on health state preferences. Med Care 2002; 40 (11): 1068-79
20. Verkooijen HM, Buskens E, Peeters PH, et al. Diagnosing nonpalpable breast disease: short-term impact on quality of life of large-core needle biopsy versus open breast biopsy. Surg Oncol 2002; 10 (4): 177-81
21. Hamashima C. Long-term quality of life of postoperative rectal cancer patients. J Gastroenterol Hepatol 2002; 17 (5): 571-6
22. Norum J, Vonen B, Olsen JA, et al. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost-effectiveness analysis. Ann Oncol 1997; 8 (1): 65-70
23. Homs MY, Essink-Bot ML, Borsboom GJ, et al. Quality of life after palliative treatment for oesophageal carcinoma: a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer 2004; 40 (12): 1862-71
24. Wildi SM, Cox MH, Clark LL, et al. Assessment of health state utilities and quality of life in patients with malignant esophageal dysphagia. Am J Gastroenterol 2004; 99 (6): 1044-9
25. Krabbe PF, Peerenboom L, Langenhoff BS, et al. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res 2004; 13 (7): 1247-53
26. McMillan DC, Wigmore SJ, Fearon KC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79 (3-4): 495-500
27. O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 1998; 32 (2): 76-80
28. Schneider SM, Pouget I, Staccini P, et al. Quality of life in longterm home enteral nutrition patients. Clin Nutr 2000; 19 (1): 23-8
29. Doorduijn J, Buijt I, Holt B, et al. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 2005; 75 (2): 116-23
30. Norum J, Angelsen V, Wist E, et al. Treatment costs in Hodgkin's disease: a cost-utility analysis. Eur J Cancer 1996; 32A (9): 1510-7
31. van Agthoven M, Vellenga E, Fibbe WE, et al. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial. Eur J Cancer 2001; 37 (14): 1781-9
32. Uyl-de Groot CA, Buijt I, Gloudemans IJ, et al. Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol 2005; 74 (2): 136-43
33. Bertaccini A, Ceccarelli R, Urbinati M, et al. BSP-PC (Bononian Satisfaction Profile-Prostate Cancer): development and validation of a 'disease-specific' questionnaire for the evaluation of health-related quality of life in patients with prostate cancer. Arch Ital Urol Androl 2003; 75 (4): 187-94
34. Korfage IJ, Essink-Bot ML, Borsboom GJ, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005; 116 (2): 291-6
35. Sandblom G, Carlsson P, Sigsjo P, et al. Pain and health-related quality of life in a geographically defined population of men with prostate cancer. Br J Cancer 2001; 85 (4): 497-503
36. Sandblom G, Carlsson P, Sennfalt K, et al. A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer 2004; 90 (6): 1163-8
37. Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer: Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001; 19 (8): 855-63
38. Ananth H, Jones L, King M, et al. The impact of cancer on sexual function: a controlled study. Palliat Med 2003; 17 (2): 202-5
39. Mantovani G, Madeddu C, Maccio A, et al. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 2004; 13 (10): 1651-9
40. Slovacek L, Slovackova B, Jebavy L. Global quality of life in patients who have undergone the hematopoietic stem cell transplantation: finding from transversal and retrospective study. Exp Oncol 2005; 27 (3): 238-42
41. Ravasco P, Monteiro-Grillo I, Camilo ME. Does nutrition influence quality of life in cancer patients undergoing radiotherapy? Radiother Oncol 2003; 67 (2): 213-20
42. Norum J. Quality of life (QoL) measurement in economical analysis in cancer: a comparison of the EuroQol questionnaire, a simple QoL-scale and the global QoL measure of the EORTC QLQ-C30. Oncol Rep 1996; 3 (4): 787-91
43. Weze C, Leathard HL, Grange J, et al. Evaluation of healing by gentle touch in 35 clients with cancer. Eur J Oncol Nurs 2004; 8 (1): 40-9
44. Desandes E, Conroy T, Briancon S, et al. Relationship between quality of life and satisfaction with care in patients treated in a Regional Centre Against Cancer. Revue Francophone de Psycho-Oncologie 2005; 4 (1): 29-35
45. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (3): 177-88
46. Conner-Spady B, Cumming C, Nabholtz JM, et al. Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res 2001; 10 (6): 479-86
47. Gerard K, Johnston K, Brown J. The role of a pre-scored multi-attribute health classification measure in validating condition-specific health state descriptions. Health Econ 1999; 8 (8): 685-99
48. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002; 11 (4): 341-53
49. Dankova I, Dlouhy M. The measurement of health status with Czech version of European quality of life questionnaire: version EQ-5D. Czech Health Policy Econ 2001; 2: 18
50. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D2 valuation model. Med Care 2005; 43 (3): 203-20
51. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38 (6): 583-637
52. Luo N, Johnson JA, Shaw JW, et al. Self-reported health status of the general adult US population as assessed by the EQ-5D and health utilities index. Med Care 2005; 43 (11): 1078-86
53. Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res 1998; 7 (2): 155-66
54. Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000; 38 (1): 115-21